Filing Flows › Interpace Biosciences (IDXG) › Capital expenditures
Interpace Biosciences (IDXG) capital expenditures by quarter
Interpace Biosciences' capital expenditures were $57K in Q2 2026 (second quarter 2026), -60% from Q1 2026. Over the last 5 quarters it ranged from $38K (Q4 2025) to $141K (Q1 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $57K | -60% | — |
| Q1 2026 | $141K | +271% | — |
| Q4 2025 | $38K | -68% | -71% |
| Q3 2025 | $117K | -9% | — |
| Q4 2024 | $129K | — | — |
Q2 2026 at a glance
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart follows the revenue to costs, profit and cash.
Questions
What is Interpace Biosciences' capital expenditures?
Interpace Biosciences' capital expenditures were $57K in Q2 2026 (second quarter 2026), -60% from Q1 2026.
How has Interpace Biosciences' capital expenditures changed?
Over the last 5 quarters it ranged from $38K (Q4 2025) to $141K (Q1 2026).